USP Names GM Of USP-China

From DCAT Value Chain Insights (VCI)

By Regulatory News posted 03-31-2015 09:07


The United States Pharmacopeial Convention announced that Bingbing Feng will become Vice President and General Manager of USP–China in Shanghai. Feng will assumed his new responsibilities on March 30, 2015.

Dr. Feng will be responsible for USP’s operations in China including all laboratory activities supporting USP’s standards-setting needs and other allied programs, with management oversight for approximately 75 staff. Established in 2007, USP’s China site completed a technical laboratory expansion in early 2014. USP also has global operations in Rockville, Md. (U.S.); Hyderabad, India and São Paulo, Brazil as well as sites in Basel, Switzerland; Accra, Ghana and Addis Ababa, Ethiopia.

For 15 years, Dr. Feng has held various positions in the pharmaceutical and contract research organization (CRO) industries in both U.S. and China. Most recently, he served as Vice President of Business Development at Alliance Pharma, Inc., in Malvern, Pa. His previous industry positions have included leadership roles in operations, business development, global manufacturing and supply and R&D at Shanghai Medicilon, Inc. (Shanghai); Frontage Laboratories, Inc. (Exton, Pa., and Shanghai); Kelly Services at McNeil Consumer Healthcare (Johnson & Johnson) (Fort Washington, Pa.) and GlaxoSmithKline (King of Prussia, Pa.). Dr. Feng studied at University of Science and Technology of China, and received a Bachelor of Science degree in chemistry (minors in mathematics and physics) from James Madison University and a Ph.D. in analytical chemistry from Purdue University. He conducted postdoctoral research at Pacific Northwest National Laboratory.

Source: USP


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription